EpCAM+ Liver Cancer Stem-Like Cells Exhibiting Autocrine Wnt Signaling Potentially Originate in Cirrhotic Patients

RITU KHOSLA, A ARCHANA RASTOGI, B GAYATRI RAMAKRISHNA, A VINIYENDRA PAMECHA, C ASHOK MUKHOPADHYAY, D MADAVAN VASUDEVAN, E SHIV KUMAR SARIN, F NIRUPMA TREHANPATI

Key Words. Epithelial cell adhesion molecule • Cancer stem cells • Cirrhosis • Hepatocellular carcinoma • Wnt

ABSTRACT

Hepatocellular carcinoma (HCC) is believed to originate from cancer stem cells (CSCs). While epithelial cell adhesion molecule (EpCAM) is a marker of normal hepatic stem cells (HSCs), EpCAM+ cells from HCC behave like CSCs. Since HCC mostly develops on a cirrhotic background, we sought to determine whether CSC-like EpCAM+ cells exist in patients with advanced cirrhosis. Both flow cytometry and immunohistochemistry showed that frequency of EpCAM+ cells in advanced cirrhosis was increased as compared to control. To determine whether increased EpCAM population in advanced cirrhosis harbors any CSC-like cells, we compared molecular and functional features of EpCAM+ cells from advanced cirrhosis (Ep+CIR; n = 20) with EpCAM+ cells from both HCC (Ep+HCC; n = 20) and noncancerous/noncirrhotic (control) (Ep+NSC; n = 7) liver tissues. Ep+CIRs displayed similarity with Ep+HCC cells including upregulated expression of stemness and Notch pathway genes, enhanced self-renewal in serial sphere assay and generation of subcutaneous tumors in nonobese diabetic/severe combined immunodeficiency mice. Moreover, transcriptome and miRNome of Ep+CIRs appeared closer to that of Ep+HCC cells than Ep+NSCs. Interestingly, more than 50% micro RNAs (miRNAs) and transcripts specifically expressed in Ep+HCCs were also expressed in Ep+CIRs. However, none of Ep+NSC specific miRNAs and only 7% Ep+NSC specific transcripts were expressed in Ep+CIRs. Further, according to gene expression and in vitro Wnt inhibition analysis, autocrine Wnt signaling appeared to be a distinct feature of Ep+CIR and Ep+HCC cells, which was absent from Ep+NSCs. EpCAM+ cells in advanced cirrhosis possibly include a population of CSC-like cells which can be explored for early diagnosis of HCC development.

SIGNIFICANCE STATEMENT

Hepatocellular carcinoma (HCC) frequently occurs in the background of cirrhosis and is believed to originate from cancer stem cells (CSCs). In this study, CSC like EpCAM+ cells were observed in patients with advanced cirrhosis. These cells had the potential to form tumors because of their limitless self-renewal through autocrine activation of Wnt signaling. Targeting these cells at initial stages of cirrhosis can help to prevent progression towards HCC, which is often detected at a stage that is not amenable to present treatment modalities.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the fifth most common cancer and second leading cause of cancer related deaths globally [1]. Despite therapeutic advancements in the treatment of HCC survival rates are poor due to presentation of the disease at advanced stage [2]. Recent studies indicate that HCC arises from liver cancer stem cells (CSCs) leading to tumor heterogeneity [3]. The origin of HCC in over 80% cases is in the milieu of chronic liver injury, mainly cirrhosis [4]. In cirrhosis, hepatocytes lose their replicative potential, resulting in the activation of normal hepatic stem cells (HSCs) [5]. Active division in presence of increased reactive oxygen species and inflammation, makes HSCs amenable to incorporate mutations and convert into CSCs, which eventually can lead to the development of HCC [6]. Thus, identification of CSCs can be of help in early diagnosis of HCC development in advanced cirrhotic patients.

Intriguingly, surface markers like epithelial cell adhesion molecule (EpCAM), CD133, CD90, CD13, and OV6 are used to identify HSCs as well as CSCs, making it difficult to differentiate between them [7]. Of these markers, EpCAM (MUC1) is an adhesion molecule commonly used to identify normal...
HSCs. It is present in developing as well as adult livers and is absent from the mature hepatocytes [8,9]. However, in HCC, EpCAM expression correlates with poor patient survival [10]. Further, EpCAM+ cells isolated from alphafetoprotein positive (AFP+) HCC tissues have been demonstrated to behave like CSCs [11,12]. Accordingly, we chose EpCAM as a marker for identification of normal stem cells (NSCs) from control and CSCs from AFP+ HCC liver tissues.

While existence of CSCs has been well demonstrated in HCC, their characterization in cirrhotic patients remains elusive, with only few reports addressing this concept [13,14]. We observed an increase in the number of EpCAM+ cells during advanced cirrhosis, warranting further studies to delineate if they have any similarity with CSCs. Since normal HSCs and CSCs express common surface markers, only certain functional characteristics can help in differentiating between them. For instance, Notch and Wnt signaling pathways are involved in the self-renewal and differentiation of normal HSCs, but, their constitutive activation has been implicated in CSCs [15–17]. In the present study, we therefore compared molecular and functional features of EpCAM+ cells from advanced cirrhosis, HCC and paired adjacent noncancerous/noncirrhotic (control) liver tissues along with EpCAM-cells from the same HCC tissues (Ep-HCC). Functional comparison was performed by checking the in vitro spheroid formation in nonadherent culture conditions and in vivo tumor formation in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. Next generation sequencing (NGS) was used to compare micro RNA (miRNA) as well as mRNA profiling in all the cell groups. NGS revealed that Wnt signaling was regulated by genes and miRNAs commonly expressed by EpCAM+ cells of both advanced cirrhosis and HCC. Owing to its well-known role in CSCs, we validated the key genes of the Wnt pathway in a larger cohort. Further, the effect of Wnt inhibitor was evaluated to determine whether any cell group is exhibiting autocrine Wnt signaling.

**PATIENTS AND METHODS**

**Patient Samples**

Liver tissues were obtained from patients undergoing Living Donor Liver Transplant (LDLT) for advanced cirrhosis (n = 20), and LDLT/resection for HCC (n = 20), at the Institute of Liver and Biliary Sciences (New Delhi, India) during 2012–2014 years. Histologically normal appearing liver tissues (noncancerous/noncirrhotic region adjacent to tumor portion) were also taken from patients having HCC on a noncirrhotic background and served as controls (n = 7). Patients between 18–80 years of age were enrolled in the study. Only HCC tissues that were AFP+ were included. Patients with alcohol, nonalcoholic steatohepatitis, hepatitis B virus (HBV) and hepatitis C virus (HCV) related HCC or advanced cirrhosis were included, while those having acute liver failure, acute-on-chronic liver failure or any viral coinfections including Human Immunodeficiency Virus (HIV)-HBV, HIV-HCV and HBV-HCV were excluded from the study. This study was approved by the Institutional Ethics Committee and informed consent was obtained from each patient or their close relatives for inclusion in the study. About 35–40 gm of liver tissues from the patients were processed and subjected to different analyses as detailed in Supporting Information Figure 1.

**Immunohistochemistry**

Histopathological analyses were performed on 5 μm thick formalin fixed paraffin embedded liver tissue sections using standard pathology laboratory protocols. In brief, sections were deparaffinized with xylene and rehydrated through graded alcohol (100, 90, 80, and 70%). Sections were then stained with Hematoxylin and eosin (H&E). Reticulin staining was performed to distinguish HCC from cirrhosis as per the standard protocol [18].

For immunohistochemistry (IHC), after rehydration, sections were treated with 3% H2O2 followed by antigen retrieval with sodium citrate buffer (pH = 6.0) and blocking with 20% goat serum. Primary anti-human EpCAM, Hepatocyte Specific Antigen (HSA) or Glypicanc-3 antibodies were used at a dilution of 1:250, 1:500, and 1:500, respectively, for staining (Santa Cruz Biotechnologies, CA, USA, https://www.scbt.com). CD133 and CD90 antibodies were procured from Abnova, Taiwan, http://www.abnova.com and used at a dilution of 1:500 and 1:200, respectively. Detection was performed using SuperSensitive Polymer-HRP IHC Detection System/DAB large volume kit (BioGenex, CA, USA, https://store.biogenex.com), in accordance with the manufacturer’s instructions. The sections were counterstained with haematoxylin to demonstrate the nuclei and were observed under the microscope. Semiquantification of EpCAM expression was defined by Quick (Q) scoring system. Q scores were calculated by multiplying the percentage of positive cells with staining intensity (0 = no, 1 = weak, 2 = moderate, and 3 = strong staining) to yield a score ranging from 0 to 300.

**Enrichment of EpCAM+ Cells Using Magnet Based Cell Separation**

The cell isolation procedure from liver tissues was performed by magnetic based assay with some modifications [19]. In brief, tissue explants were washed with phosphate buffer saline (PBS) and chopped into small pieces. After digestion with 0.05% type IV collagenase (Worthington Biochemical Corporation, NJ, USA, http://www.worthington-biochem.com) for 30 minutes at 37°C, tissues were again minced and the cell suspension was passed through a 70-μm cell strainer (BD Biosciences, NJ, USA, https://www.bdbiosciences.com) to remove tissue debris. Red blood cells (RBCs) were lysed by 1x RBC lysis buffer (Stem Cell Technologies, Vancouver, Canada, https://www.stemcell.com) and the cells were washed again with PBS. An aliquot of the single cell suspension was used to determine the percentage of EpCAM+ cells by flow cytometry. Viable and nonviable cells were counted by trypan blue staining and then used to isolate EpCAM+ cells by magnet assisted cell sorting. In brief, depending on the cell number, they were labeled with appropriate amount of EpCAM+ selection cocktail using EpCAM+ Cell Isolation Kit (Stem Cell Technologies, Vancouver, Canada), according to manufacturer’s instructions. Purity of EpCAM+ and EpCAM-sorted cells were evaluated by flow cytometry.

**Flow Cytometric Analysis**

Cells were stained with anti-human EpCAM PE (eBiosciences, CA, USA, http://www.ebioscience.com/) antibody for 20 minutes at RT. After washing with PBS, cells were acquired on BD FACS Calibur (BD Biosciences, San Jose, CA) and data was analyzed using Flow Jo software version 7.5.
Quantitative Reverse-Transcription Polymerase Chain Reaction

Total RNA was extracted from the sorted cells’ pellet using MIRVana kit (Ambion, TX, USA, https://www.thermofisher.com/in/en/home/brands/invitrogen/ambion.html). The concentration of RNA was measured using Nanodrop ND-1000 spectrophotometer (ThermoFisher Scientific, DE, USA, http://www.thermofisher.com/in/en/home.html) and quality was checked by bioanalyzer (Agilent Technologies, CA, USA, www.agilent.com). The RNA samples (~50 ng) were then amplified using a random hexamer primer to form complimentary DNA.

Quantitative reverse-transcription polymerase chain (qRT-PCR) reaction was performed with a SYBR Green PCR Kit (Applied Biosystems, DE, USA, https://www.thermofisher.com/in/en/home/brands/applied-biosystems.html) using an ABI PRISM 7700 Sequence Detector and Viia 7 software (Applied Biosystems, DE, USA). The primers of selected genes were designed using Primer 3 software (Supporting Information Table 1). The gene expression level was normalized against 18S RNA (control gene). Subsequently, the relative gene expression values were determined using log of \( 2^{-\Delta\Delta CT} \).

Spheroid Assay

Sorted cells obtained after magnetic based cell separation were suspended in 0.9% methyl cellulose in knockout Dulbecco’s modified Eagle medium/nutrient mixture F-12 (DMEM/F12) media, containing 10% knockout serum replacement, 1% Penicillin-Streptomycin-Amphotericin B, 20 ng/ml human recombinant Epidermal Growth Factor and 10 ng/ml human recombinant Fibroblast Growth Factor (Life Technologies, CA, USA, https://www.thermofisher.com/in/en/home/brands/invitrogen.html) and seeded in a six-well ultralow attachment plate (Corning Inc., Corning, NY, USA, www.corning.com) at a density of about 5,000 cells per well. Plates were incubated at 37°C and 5% CO₂, for 12–14 days, during which fresh media was added every third day. When most of the spheroids attained at least 50 μm diameter, they were washed with PBS, trypsinized and repassaged under same culture conditions. Spheroids were maintained for a total of six passages. After each passage the size and number of spheroids were recorded.

Animal Studies

Twenty-five thousand or 50,000 freshly isolated EpCAM+ cells were resuspended in 200 μl of a 1:1 mixture of DMEM/F12:Matrigel (BD Biosciences, NJ, USA) and subcutaneously injected into 6 to 8 weeks old male nonobese diabetic/severe combined immune deficiency (NOD/SCID) mice (The Jackson Laboratories, CA, USA, https://www.jax.org/). For each cell type (Ep+NSC, Ep+CiR, Ep+HCC, and Ep-HCC), three mice were injected with three different patient samples. Formation of tumor was observed till 8–10 weeks after injection of cells. Tumor volume was calculated by using the formula \( V = \frac{4}{3}\pi \times D^3 \), where \( D \) is the diameter of the tumor in millimeters. The experimental protocol was approved by Institutional Animal Ethics Committee (IAEC 298/12), National Institute of Immunology, India. All animals were treated with humane care. They were kept in individual ventilated cages and fed with autoclaved acidified water and irradiated food ad libitum.

Next Generation Sequencing for Small RNA and mRNA

Detailed protocol is given in Patients and Methods section of Supporting Information annexure.

Wnt Inhibitor Assay

EpCAM+ cells were plated at a density of 10,000 cells per well in ultra-low attachment plates with IWP12 (Inhibitor of Wnt production compound 12) (Sigma-Aldrich, Tokyo, Japan, www.sigmaaldrich.com/) at a concentration of 5 μM per well. Spheroid formation was compared in terms of both size and number with corresponding cells plated without the inhibitor.

Statistical Analysis

Data were analyzed using the statistical software Prism (version 5; GraphPad Software) and are reported as mean ± standard error mean (SEM). For analysis of the clinical data, Kruskal-Wallis Test followed by probability adjustment by Mann-Whitney test was performed. Here \( p \leq 0.01 \) was considered significant. For other experiments the unpaired Student’s t test was performed to compare two mean values and \( p \) values < 0.05 were considered statistically significant.

RESULTS

Clinicopathological Features of Patients

The demographic profile of all the subjects enrolled in this study is shown in Table 1. Out of total patients with advanced cirrhosis and/or HCC, 20% were affected due to excessive alcohol intake and another 20% with HBV infection. Only one patient had HCV related HCC. Remaining 57% patients had unknown etiology. Male to female ratio in patients with advanced cirrhosis or HCC was same. There was no significant difference in the AFP levels of cirrhotic and HCC patients due to high standard deviation. Out of 20 cirrhotic patients, only one patient (5%) had AFP above the threshold value of 10 ng/ml. In case of HCC as well, only 20% had AFP values above the threshold. AST and ALT levels in both the groups were also similar. The serum bilirubin and International normalized ratio (INR) levels were higher in cirrhotic patients as compared to HCC patients and so were the MELD scores.

Histopathological Characterization of the Tissue Specimen

Histologically normal, cirrhotic and HCC liver tissues used in the present study were initially validated by a pathologist. HCC occurred in the background of cirrhosis or in the absence of cirrhosis as depicted in the gross pictures (Supporting Information Fig. 2A). Histologically normal liver tissues obtained from noncancerous/noncirrhotic region adjacent to tumor were classified on the basis of no significant appearance of fibrosis and single chord arrangement of benign hepatocytes in HE sections (Supporting Information Fig. 2B). Cirrhotic tissues were composed of regenerative parenchyma (Supporting Information Fig. 2C). HE staining of HCC specimen showed the characteristic trabecular and pseudoglandular architecture (Supporting Information Fig. 2D). Malignant hepatocytes were polygonal cells displaying varying degree of nuclear enlargement and atypia. Reticulin staining is a silver impregnation technique used to delineate reticulin fibers and is therefore useful in distinguishing HCC (which is reticulin deficient due to thick chord arrangement of cells) from cirrhosis. Reticulin staining revealed a reticulin poor HCC in...
contrast to preserved reticulin staining of cirrhotic liver tissue specimens. We used HCC tissues which showed AFP positivity in cirrhotic liver sections confined to the hepatic progenitor cells. In the increased EpCAM population of cirrhotic liver tissues, their tissues have been shown to behave like CSCs [11], for subsequent experiments we used HCC tissues which showed AFP positivity in IHC.

Increased Expression of EpCAM in Cirrhotic Liver Tissues

We compared the expression of some of the most commonly used surface markers for CSC identification namely EpCAM, CD133, and CD90 in the respective tissue sections by IHC (Fig. 1A). A very weak expression of CD133 was observed in the control and cirrhotic liver sections confined to the hepatic progenitor cells. Within the HCC sections as well, weak to moderate cytoplasmic staining of CD133 was observed. In accordance with the published reports [20], CD90 expression was mainly detected in inflammatory and endothelial cells. There was not much difference in the level of CD90 expression in control and cirrhotic liver tissue. The HCC section showing maximum expression of CD90 is represented in the figure, although most of the other sections showed weak or no expression. The expression of EpCAM was detected mainly in bile ductules of control liver tissues and was completely absent from mature hepatocytes. IHC in cirrhosis revealed that EpCAM expression was increased particularly near the portal areas in the bile ductules, oval cells, and intermediate hepatocytes. HCC tissues showed strong membranous staining of EpCAM. Flow cytometric analysis also showed an increase in number of EpCAM+ cells in advanced cirrhosis as compared to histologically normal tissue specimens (Fig. 1B). However, quantification of both flow cytometric and IHC data demonstrated that the frequency of EpCAM+ cells was highest in HCC tissues (Fig. 1C). These results clearly indicate an increase in the EpCAM expression during progression toward HCC. However, to establish the presence of CSCs in the increased EpCAM population of cirrhotic liver tissues, their molecular and functional characterization was performed as described in the following sections.

EpCAM+ Cells from Cirrhotic Livers Display Enhanced Self-Renewal

Deregulation of various signaling pathways has been implicated in maintaining self-renewal of CSCs [21]. For instance, Notch signaling promotes proliferation of CSCs. Further, Nanog, Oct4, and Sox2 are key regulators of stemness involved in carcinogenesis [22–24]. Interestingly, these stemness genes are direct targets of EpCAM [25]. We therefore wanted to compare the level of expression of these genes in EpCAM+ cells isolated from control (Ep+NSC), advanced cirrhosis (Ep+CIR) and AFP+ HCC tissues (Ep+HCC). The purity of the sorted EpCAM+ cells was between 85 and 90% (Supporting Information Fig. 3). Expressions of Nanog, Oct4, and Sox2 and Notch signaling genes (Notch 1, 2, 3, Jag1, and Hey2) were significantly higher (p < .05) in Ep+CIR and Ep+HCCs in comparison to Ep+NSC (Fig. 2A, 2B, Supporting Information Table 2). However, there was no significant difference in the expression of these genes between Ep+CIRs and Ep+HCCs. Further, Notch 4 showed no significant difference in the expression between all the three study groups. To monitor the validity of sorted Ep+HCCs, the expression of all the above genes was also analyzed in Ep-HCCs. All the genes showed decreased expression in Ep-HCCs as compared to Ep+HCC cells. Self-renewal of CSCs can be established in vitro by serial spheroid assay [26]. We checked the spheroid forming ability of EpCAM+ cells by growing them in nonadherent serum free culture. A striking difference was observed in the size of the spheroids formed by Ep+NSC, Ep+CIR, and Ep+HCC cells (Fig. 2C). Violin plot clearly demonstrated that Ep+CIR spheroids were varied in size (40–126 μm). While most of them were smaller in size like Ep+NSC (40–68 μm), a small proportion were bigger like Ep+HCC (87–138 μm) spheroids (Fig. 2D). This observation affirms the existence of a heterogeneous population of EpCAM+ cells within advanced cirrhotic liver tissues. Flow cytometric analysis revealed the enrichment of EpCAM+ cells within the spheroids, thereby demonstrating their clonal expansion (Fig. 2E).

The spheroids were cultured for six passages. Number of spheroids formed by EpCAM+ cells isolated from both HCC and advanced cirrhosis increased exponentially at every passage. On the contrary, number of spheroids from Ep+NSCs increased till third passage following which it attained a stationary phase (Fig. 2F). Taken together, these results suggest that EpCAM+ cells from advanced cirrhosis have limitless self-renewal capacity unlike Ep+NSCs.

Ep+CIR Cells Possess Tumor Forming Ability

The gold standard for testing CSCs is their ability to generate tumors upon injection into mice [27,28]. We subcutaneously injected 25,000 and 50,000 Ep+NSC, Ep+CIR, and Ep+HCC, and also Ep-HCC cells in flanks of NOD/SCID mice. Ep+HCC cells formed tumors in all the three mice upon transplantation of 25,000 cells/mice (Fig. 3A). Ep+CIR cells also generated subcutaneous tumors albeit when higher cell number was used, while no tumor formation was observed with 25,000 cells (Fig. 3A, 3B). Ep+NSCs did not generate any tumor even with 50,000 cells/mice whereas EpCAM+ HCC cells formed a very small tumor in one out of three mice injected with 50,000 cells. Tumor nodules formed by each cell type were confirmed by histopathological examination.

Table 1. Demographic profile of the study group patients

| Parameters     | Advanced cirrhosis (n = 20) | HCC (n = 20) | p value |
|----------------|-----------------------------|-------------|---------|
| Age (years)    | 47.17 ± 10.94               | 57.2 ± 11.75| .129    |
| Sex            | 04.01                       | 04.01       | —       |
| Creatinine (mg/dl) | 0.78 ± 0.29                | 0.78 ± 0.19 | 1       |
| INR            | 1.64 ± 0.33                 | 1.22 ± 0.25 | .004    |
| Bilirubin (mg/dl) | 3.64 ± 3.03                | 1.72 ± 2.07 | .012    |
| AST (IU/L)     | 51.92 ± 23.26              | 79.45 ± 53.9| .87     |
| ALT (IU/L)     | 29.5 ± 15.7                | 63.34 ± 35.7| .77     |
| AFP (ng/ml)    | 4.2 ± 1.5                  | 136.3 ± 273.8| .16     |
| (>10 ng/ml)    | 1 (5)                      | 4 (20)      | <.000   |
| MELD Score     | 19.6 ± 7                   | 8.9 ± 2.9   | <.000   |

All values are expressed as mean ± SD or number (%); p < .017 = significant.

Abbreviations: —: no data; AFP: alpha fetoprotein; ALT: alanine aminotransferase; AST: aspartate transaminase; HBV: Hepatitis B virus; HCV: Hepatitis C virus; INR: International Normalized Ratio; M:F, male:female; MELD: model for end stage liver disease.
Representative images shown in Figure 3C reveal characteristic histomorphological features of HCC with presence of thick trabeculae surrounded by sinusoidal cell along with focal pseudo-glandular arrangement of malignant hepatocytes. These cells display enlarged nucleus with high nucleocytoplasmic ratio, conspicuous nucleoli and moderate to abundant eosinophilic cytoplasm. All tumor sections showed strong membranous immunostaining for EpCAM.

The low frequency of tumor formation with cirrhotic EpCAM+ cells cannot be fully explained by number of injected cells alone. It may be affected by experimental artefacts like viability and purity of the injected cells. Further, the percentage of CSCs within the total EpCAM+ cell population from cirrhotic liver is expected to be very low and might vary from patient to patient. Nevertheless, it is reasonable to conclude from this result that EpCAM+ cells from advanced cirrhosis include a subset of CSCs.

**EpCAM EXPRESSION INCREASES DURING ADVANCED CIRRHOSIS**

![Image](https://www.StemCellsTM.com)

**Figure 1.** Advanced cirrhosis show increased expression of EpCAM+ cells. (A): Representative photomicrographs for immunohistochemical (IHC) analysis of EpCAM, CD133, and CD90 (brown) on paraffin-embedded sections of histologically normal \((n = 7)\), advanced cirrhotic \((n = 20)\), and HCC \((n = 20)\) liver tissues. Slides were counterstained with hematoxylin \((x200; \text{Scale bars} = 100 \mu m)\). (B): Representative dot plots for flowcytometric analysis of total liver cells from same patient groups with antihuman phycoerithrin-EpCAM antibody. (C): Scatter plot is representing the percentage of EpCAM+ cells in each patient as determined by flow cytometry (left panel). Quantitation of IHC data is represented as a bar graph (right panel). \(p < .05\) = significant. Abbreviations: EpCAM, epithelial cell adhesion molecule; HCC, hepatocellular carcinoma.

EpCAM+ Cir Cells Carry Ep+HCC Cell Like Signatures in Advanced Cirrhotic Livers

In order to decipher the similarity between Ep+HCC and Ep+CIR at the molecular level, NGS was performed in Ep+HCC, Ep+CIR, Ep+NSC, and Ep-HCC cell populations. Deep sequencing of transcripts and small RNAs resulted in an average of 15 million reads per sample for small RNome and 72 million reads per sample for transcriptome (Supporting Information Fig. 4A, 4B). Unique Tag distribution of small RNAs in Ep+NSCs was significantly higher as compared to the other three groups of cells (Supporting Information Fig. 4C). A total of 24,196 transcripts and 389 miRNAs were
detected to be expressed collectively in the four samples (as per the criteria mentioned in the methods).

**Ep+HCC Cell Specific miRNA Signatures Seen in Ep+1CIR Cells.**

Unsupervised hierarchical clustering of the differentially expressed miRNAs clearly showed that Ep+1CIRs and EP+1HCC cells clustered together while Ep-HCC and Ep+1NSC miRNAs did not largely overlap with Ep+1CIR (Fig. 4A). In order to obtain CSC related miRNAs, Ep+1HCC miRNome was compared with Ep+1NSC and Ep-HCC (< or >2-fold and p < .05). Further, to determine CSC related miRNAs in advanced cirrhosis, Ep+1CIR cells were compared with Ep+1NSCs and to together the number of differentially expressed miRNAs in the three comparisons was plotted in one Venn diagram. Twenty seven out of 43 upregulated (63%) and 16 out of 34 downregulated (47%) miRNAs in Ep+1CIR were also similarly differentially expressed in Ep+1CIR (Fig. 4B). Interestingly, 11 out of 22 Ep+1HCC specific miRNAs (141, 18a, 511, 561, 548o, 200a, 200b, 224, 31, 7-1, and 210) were also expressed in Ep+1CIR cells but not in Ep+1NSCs and Ep-HCCs (Fig. 4C; Supporting Information Figure 2).

---

**Figure 2.** EpCAM+ cells from advanced cirrhosis display enhanced self-renewal. (A, B): Expression of stemness and Notch signaling genes in sorted Ep+1NSC (n = 5), Ep+1CIR (n = 20), Ep+1HCC (n = 20), and Ep+1HCC (n = 20) cells determined by quantitative reverse transcription-polymerase chain reaction. Results are expressed as mean of log 2\( \Delta \Delta Ct \) ± standard error. (*, p < .05). (C): EpCAM+ cells from normal, advanced cirrhosis and HCC formed spheres under nonadherent culture conditions (n = 5 in each group) (Images from first passage, x200). (D): Spheres from Ep+1CIR were heterogeneous in size as represented by two lobes in the Violin plot. Vertical axis is showing the range and mean size of the spheres (n = 3 in each group). (E): Flow cytometric analysis of single cells from the spheres showed enrichment of EpCAM+ cells in them. (F): After every 14–16 days, spheres were trypanosed to form single cells and 5,000 cells per well were re-plated with fresh medium till six passages. Number of spheres in each sample was counted after every passage and plotted in a graph (n = 3 in each group) (values are represented as mean ± SEM). Abbreviations: Ep+1CIR, EpCAM+ cells from advanced cirrhosis; Ep+1HCC, EpCAM+ cells from HCC, Ep+1NSC, EpCAM+ cells from noncancerous/noncirrhotic (control); HCC, hepatocellular carcinoma; NSCs, normal stem cells; Oct4, octamer-binding transcription factor 4; Sox2, sex determining region Y-box 2.
Ep+ CIR cells possess tumor forming ability.

(A): Representative images of tumors derived from nonobese diabetic/severe combined immunodeficiency mice induced by Ep+ CIR, Ep+ HCC, and Ep+ HCC, after 8 weeks of subcutaneous injection (50,000 cells per mice) (n = 3 in each group).

(B): Table showing volume (mean ± SD) and incidence of tumor formation with different cell types (n = 3 in each group).

(C): Histopathological characterization by HE staining (upper panel) and immunohistochemical analysis of EpCAM expression in tumors (lower panel) (×200; Scale bars = 100 μm).

EpCAM+ cells from advanced cirrhosis possess tumor forming ability. In Figure 3, we observed that EpCAM+ cells derived from mouse advanced cirrhosis tumors formed tumors after 8 weeks of subcutaneous injection. This indicates that EpCAM+ cells possess tumor forming ability, which is consistent with previous studies showing that EpCAM+ cells are enriched in CSCs.

Ep+ HCC specific gene signature in advanced cirrhosis.

In parallel with the deep sequencing based miRNA studies, we also investigated the global changes in gene expression patterns associated with Ep+ NSC, Ep+ HCC, Ep+ CIR, and Ep+ HCC cell populations. Unsupervised hierarchical clustering of the differentially expressed transcripts reiterated the observation that Ep+ CIR profile was closer to that of Ep+ HCC compared to Ep+ NSC and Ep+ HCC cells, indicating the presence of dominant molecular signature of CSCs during advanced cirrhosis.

Venn diagram depicting the comparison of Ep+ HCC with Ep+ NSC and Ep+ HCC, and Ep+ CIR with Ep+ NSC showed that 1,130 upregulated and 40 down regulated genes in Ep+ HCCs were also similarly differentially expressed in Ep+ CIRs (Fig. 4E). A significant number of transcripts (2082) were specifically expressed only in Ep+ CIR and Ep+ HCC (Fig. 4F; Supporting Information Table 4), which together with 11 Ep+ HCC and Ep+ CIR specific miRNAs, could be a representative signature of Ep+ HCCs in the cirrhotic liver. On the contrary, very few transcripts (332) were expressed exclusively in both Ep+ NSC and Ep+ CIR cells.

Taken together, the results clearly indicate that Ep+ CIRs are similar to Ep+ HCCs and are distinct from Ep+ NSC cells at the molecular level.

Pathways regulated by miRNAs/transcripts commonly expressed by Ep+ CIR and Ep+ HCC cells.

miRNAs and genes that were (a) specifically expressed only in Ep+ HCC and Ep+ CIR, (b) commonly upregulated in Ep+ HCC and Ep+ CIR, and (c) commonly downregulated in Ep+ HCC and Ep+ CIR, were subjected to significant gene ontology and pathway analysis to identify important biological events regulated by them (Fig. 5A). Wnt, Notch, mitogen-activated protein kinase, and c-Jun N-terminal kinase (JNK) were some of the important pathways regulated by commonly expressed miRNAs and transcripts of Ep+ CIR and Ep+ HCCs (Fig. 5B).

EpCAM+ cells of advanced cirrhosis patients exhibit autocrine Wnt signaling.

Among the commonly expressed pathways, Wnt signaling was of particular interest due to its role in stem cell self-renewal and cancer development. Further, Yamashita et al. recently reported that Wnt/β-catenin signaling augments self-renewal and inhibits the differentiation of liver CSCs by the expression of the stem cell marker EpCAM [11]. Therefore, we chose to validate the expression of Wnt pathway genes in EpCAM+ cells from control, advanced cirrhotic and HCC tissues.

Signaling molecules of Wnt pathway were >2-fold upregulated in Ep+ CIR and Ep+ HCC compared to Ep+ NSC cells (Fig. 6A), particularly Wnt3, which is a ligand in canonical Wnt signaling. It is reported that the secretion of Wnt proteins require Evi/Wls (Evenness interrupted/Wntless), a multipass transmembrane protein. It acts as a cargo receptor for Wnt proteins, shuttling them from the Golgi to the plasma membrane where they act in an autocrine or paracrine manner to activate Wnt signaling pathways [29]. Therefore, we also checked the expression of Evi/Wls in the three study groups. Although highest in HCC, the expression of Evi/Wls was significantly increased in EpCAM+ cells from advanced cirrhotic patients than controls (Fig. 6A), indicating the existence of autocrine Wnt signaling in them. In addition, a significant increase in expression of β-catenin and two of its well-known targets c-Myc and Cyclin D1, was also noted in both Ep+ CIR and Ep+ HCC cells.

Chen et al. in 2009 reported that IWP compounds act on porcupine, a member of the membrane-bound O-acyltransferase (MBOAT) family and inhibit palmitoylation of Wnt proteins, which is essential for their secretion and signaling ability [30]. Therefore, we cultured the EpCAM+ cells from advanced cirrhosis and HCC patients in ultra-low attachment plates with and without the Wnt inhibitor, IWP12. The number and size of spheroids formed in the presence of IWP12 was significantly reduced with Ep+ CIR and Ep+ HCC cells when compared to corresponding EpCAM+ cells.
grown without the inhibitor (Fig. 6B, 6C). The number of spheroids formed was reduced by 44% and 54%, respectively. The responsiveness to Wnt inhibition confirmed that both Ep+1CIR and Ep+1HCCs exhibit autocrine Wnt signaling unlike the Ep+1NSCs. Cumulatively, the observation that Ep+1CIR cells showed increased expression of Evi/Wls and Wnt3 and were even responsive to Wnt inhibitor, IWP12, re-emphasized their molecular similarity to Ep+1HCCs.

**DISCUSSION**

HCC frequently occurs in the background of cirrhosis and is believed to originate from CSCs [31]. Cirrhosis is marked by regenerative nodules resulting from localized proliferation of hepatocytes in response to liver injury. These nodules can eventually progress to become dysplastic nodules or HCC [32]. In chronic liver injury, ductular reactions become prominent due to suppressed...
accordance with these reports, we too observed increased expression of EpCAM+ cells near the ductular regions of advanced cirrhosis liver sections. An increase in the EpCAM expression together with increased rate of cellular proliferation could possibly dictate the fate toward transformation into CSCs. Existence of CSCs during cirrhosis was earlier addressed by Sun et al. However, they used the complete cirrhotic tissue to show its tumorigenicity and did not characterize it at cellular level [13]. More recently in a mouse model, a collagenase resistant cell population was identified within cirrhotic livers which could generate tumors in mice with chronic damage and compensatory proliferation in their liver. These cells were shown to overexpress EpCAM and were called as HCC progenitor cells [14]. The present study, to our knowledge, is the first to report the existence of EpCAM+ cancer stem-like cells in advanced cirrhotic patients. All the patients included as advanced cirrhosis in this study had undergone liver transplantation.

Using molecular and functional parameters we determined CSC like traits in Ep+/CIRs. Notch is a well-studied pathway implicated in the regulation of both normal HSCs and CSCs. Notch signaling was activated in HSCs during biliary regeneration, but was restricted during hepatocellular regeneration [36]. On the contrary, a previous study indicated increased Notch activity in CSCs as compared to HSCs in breast cancer [37]. Cirrhotic patients recruited in this study had primary hepatocellular injury rather than primary cholangiocyte injury (Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis patients were not enrolled in the study). Yet, we observed that Jag1, Notch 1, Notch 2, Notch 3, and Hey2 were significantly upregulated in both Ep+/CIR and Ep+/HCC cells as compared to Ep+/NSCs, indicating the appearance of CSC like phenotype during advanced cirrhosis.

It is well documented that self-renewal capacity of a cell can be quantified by spheroid formation in vitro, in particular by analyzing the number and size of cells within the spheroid and the ongoing generation (self-renewal) of spheroids through repeated passages. [38]. Ep+/CIR cells formed few large sized spheroids compared to the majority of smaller ones, providing direct evidence for the presence of a heterogeneous population of EpCAM+ cells within the cirrhotic livers. Increased spheroid formation over repeated passages reflected the limitless proliferation capabilities of Ep+/CIR cells. Further, unlike Ep+/NSCs, Ep+/CIR cells were capable of generating tumors when injected subcutaneously in NOD/SCID mice. Ep+/CIR cells thus exhibited enhanced self-renewal with uncontrolled proliferation and tumor formation, all of which are hallmark features of a CSC [39].

In order to determine the similarity at the molecular level between Ep+/CIR and Ep+/HCC cells, NGS was performed. Sequencing data deciphered that JNK, MAPK and Wnt signaling were some of the important pathways regulated by miRNA and genes commonly shared by Ep+/CIR and Ep+/HCC cells. JKMs were earlier considered to have pro-apoptotic functions in response to stress, inflammatory or oncogenic signals [40]. However, emerging evidence now suggests that the JKMs, especially JNK1, play an important role in the malignant transformation of cells and in tumorigenesis [41]. Studies have also shown the association of higher JNK1 activation with a poorer prognosis as well as overexpression of EpCAM, CD24, CD133, KRT19, and AFP in HCC [42]. Indeed, we too observed an over-expression of JNK1 in Ep+/CIR and Ep+/HCC cells as compared to Ep+/NSC (data not shown).

Interestingly, 11 out of 22 Ep+/HCC specific miRNAs were also expressed in Ep+/CIRs. Among these, mir-511 is negatively associated with overall survival of HCC patients [43]. mir-210 promotes...
migration and invasion of HCC cells [44]. miR-141 has been reported to confer resistance to 5-flurouracil in HCC cells [45]. Importantly, miR-18a and 224 have been proposed as serum biomarkers for diagnosis of HCC [46,47]. Thus, most of the 11 miRNAs are associated with imparting tumorigenic properties in HCC cells and their increase expression in EpCAM+ CSCs reflects their transformed status. However, role of these miRNAs in CSCs still needs to be elucidated. Additionally, the functions of miR-548o, 561, and miR-7-1 have not yet been well explored in context of both HCC and CSCs. Wnt signaling is an important proliferation pathway, well documented in the pathogenesis of many cancers. Importantly, Yamashita et al. showed that Wnt/β-catenin enriches the EpCAM+ CSCs by enhancing their self-renewal and inhibiting their differentiation [48]. We therefore validated the expression of Wnt pathway genes by qRT-PCR and found them to be upregulated in both EpCAM+CSCs and EpCAM+HCC cells. Colon CSCs have been shown to demonstrate autocrine Wnt secretion via Evi/Wls, a transporter of Wnt [49]. Present data showed significantly increased expression of evi and wnt3 in EpCAM+CSCs and EpCAM+HCC cells. Subsequently, in the presence of Wnt inhibitor (IWP 12), the spheroid forming ability of both group of cells reduced significantly. To the best of our knowledge, these results report for the first time, the existence of autocrine Wnt signaling in EpCAM+ CSCs from HCC. In addition, presence of autocrine Wnt signaling in EpCAM+CSCs strengthen our notion of existence of CSC like cells during advanced cirrhosis.

**CONCLUSION**

In conclusion, we report the existence of a small population of EpCAM+ CSC like cells in advanced cirrhosis, which have the potential to develop into HCC because of their limitless self-renewal through autocrine activation of Wnt signaling. Targeting these cells at initial stages of advanced cirrhosis can help to prevent progression toward HCC, which is often detected at a stage that is not amenable to present treatment modalities. However, to target these cells at cirrhotic stage, we need to identify an efficient biomarker which is preferentially expressed in CSCs and not NSCs. Further investigations of CSCs specific miRNAs in patient

![Figure 6. EpCAM+ cells from advanced cirrhosis and HCC exhibit autocrine Wnt signaling. (A): Real time analysis showed >2-fold upregulation of Wnt pathway genes including evi/wls (Wnt transporter) in both EpCAM+CSCs (n = 20) and EpCAM+HCC (n = 20) as compared to EpCAM+NSCs (n = 5). Results are expressed as mean of log 2^ΔΔCt ± standard error. (*, p < 0.05). (B, C): In the presence of IWP12 (an inhibitor of Wnt acyltransferase), spheroids formed by EpCAM+CSCs of both advanced cirrhosis and HCC were reduced in size as well as number. There was no significant effect of the inhibitor on spheroid formation of EpCAM+NSCs (x200; Scale bars = 100μm) (n = 3 in each group). (p < 0.05 = significant). Abbreviations: EpCAM, epithelial cell adhesion molecule; EpCAM+CSCs, cells from advanced cirrhosis; EpCAM+HCC, EpCAM+ cells from HCC, EpCAM+NSCs, EpCAM+ cells from noncancerous/noncirrhotic (control); HCC, hepatocellular carcinoma; NSCs, normal stem cells.](image-url)
serum samples may highlight their use as biomarkers for early diagnosis of HCC at cirrhotic stage.

ACKNOWLEDGMENT

This study was supported by Grant-in-Aid from Department of Biotechnology (Grant No. BT/PR5345/MED/31/157/2012), Ministry of Science and Technology, New Delhi, India.

AUTHORS CONTRIBUTIONS

R.K.: collection of patient samples, laboratory experiments, data acquisition, analysis and interpretation, statistical analysis, manuscript writing; A.R.: interpretation of immunohistochemistry data; V.P.: provision of transplant/resected liver tissue specimens and intellectual inputs; A.M.: provision of animal house facility, supervision of animal experiments and revision of manuscript; M.V.: acquisition and analysis of NGS data; G.R.: critical intellectual inputs and manuscript editing; S.K.S.: critical review of the concept, experimental designs and revision of the article; N.T.: conceptual design of study and critical revision of the article for important intellectual content.

REFERENCES

1. Chua HH, Tseui DJ, Lee PH et al. RBMV, a novel inhibitor of glycogen synthase kinase 3beta, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma. Hepatology 2015;62:1480–1496.
2. Cancro WG, Stewart AK, Mech CR. The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: Improved survival of surgically resected patients, 1985-1996. Cancer 2000;88:912–920.
3. Sell S. Cellular origin of hepatocellular carcinomas. Semin Cell Dev Biol 2002;13:419–424.
4. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118–1127.
5. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006;25:3818–3822.
6. Alison MR, Islam S, Lim S. Stem cells in liver regeneration, fibrosis and cancer: The good, the bad and the ugly. J Pathol 2009;217:282–298.
7. Liu LL, Fu D, Ma Y et al. The power and the promise of liver cancer stem cell markers. Stem Cells Dev 2011;20:2023–2030.
8. Turner R, Lozoya O, Wang Y et al. Human hepatic stem cell and maturational liver lineage biology. Hepatology 2011;53:1035–1045.
9. Schmelzeier E, Zhang L, Bruce A et al. Human hepatic stem cells from fetal and postnatal donors. J Exp Med 2007;204:1973–1987.
10. Ji J, Yamashita T, Budhu A et al. Identification of microRNA-181a by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009;50:472–480.
11. Yamashita T, Ji J, Budhu A et al. EpCAM-positive hepatocellular carcinoma cells are tumour-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136:1012–1024.
12. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010;52:280–281.
13. Sun YL, Yin SY, Xie HY et al. Stem-like cells in hepatitis B virus-associated cirrhotic livers and adjacent tissue to hepatocellular carcinomas possess the capacity of tumorigenicity. J Gastroenterol Hepatol 2008;23:1280–1286.
14. He G, Dhar D, Nakagawa H et al. Identification of liver cancer progenitor whose malignant progression depends on autocrine IL-6 signaling. Cell 2013;155:384–396.
15. Dontu G, Jackson KW, McNicholas E et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004;6:R605–615.
16. Wang Z, Li Y, Baniere J et al. Emerging role of Notch in stem cells and cancer. Cancer Lett 2009;279:8–12.
17. Panniuti A, Foreman K, Rizzo P et al. Targeting Notch to target cancer stem cells. Curr Cancer Res 2010;16:3141–3152.
18. Yao S, Zhang J, Chen H et al. Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD117 and reticulin staining in hepatocellular carcinoma. J Histochim Cytochem 2013;61:639–648.
19. Ho DW, Yang ZF, Yi K et al. Gene expression profiling of liver cancer stem cells by RNA-sequencing. PLoS One 2012;7:e37159.
20. Yamashita T, Honda M, Nakamoto Y et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology 2013;57:1484–1497.
21. Takebe N, Miele L, Harris PJ et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update. Nat Rev Clin Oncol 2015;12:445–464.
22. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663–676.
23. Wen J, Park YJ, Park KH et al. Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Pancreas 2010;39:622–626.
24. Muller M, Herrmann PC, Liebau S et al. The role of pluripotency factors to drive stemness in gastrointestinal cancer. Stem Cell Res 2016;16:349–357.
25. Lu TY, Ly RM, Liao MY et al. Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. J Biol Chem 2010;285:8719–8732.
26. Pastrana E, Silva-Vargas Y, Doetsch F. Eyes wide open: A critical review of sphere formation as an assay for stem cells. Cell Stem Cell 2011;8:486–498.
27. Gilbert CA, Ross AH. Cancer stem cells: Cell culture, markers, and targets for new therapies. J Cell Biochem 2009;108:1031–1038.
28. Hindriksen S, Bijsma MF. Cancer stem cells, EMT, and developmental pathway activation in pancreatic cancers. Cancers 2012;4:980–1035.
29. Bartscherer K, Petle N, Ingelfinger D et al. Secretion of Wnt ligands requires Evi, a conserved transmembrane protein. Cell 2006;125:523–533.
30. Chen B, Dodge ME, Tang W et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100–107.
31. Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest 2013;123:1911–1918.
32. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003;3:573–588.
33. Falkowski O, An HJ, Janus IA et al. Regeneration of hepatocyte 'buds' in cirrhosis from intrabiliary stem cells. J Hepatol 2003;39:357–364.
34. Clouston AD, Powell EE, Walsh MJ et al. Fibrosis correlates with a ductular reaction in hepatitis C. Roles of impaired replication, progenitor cells and steatosis. Hepatology 2005;41:809–818.
35. Yoon SM, Gerasimidou D, Kuwahara R et al. Epithelial cell adhesion molecule (EpCAM) marks hepatocytes newly derived from stem/progenitor cells in humans. Hepatol ogy 2011;53:964–973.
36. Boulter L, Govaere O, Bird TG et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med 2012;18:572–579.
37. Harrison H, Farnie G, Howell SJ et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010;70:709–718.
38. Dontu G, Abdallah WM, Foley JM et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253–1270.
39. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004;23:7274–7282.
40. Liu J, Lin A. Role of JNK activation in apoptosis: A double-edged sword. Cell Res 2005;15:36–42.
41. Darbin AD, Somers GR, Forrester M et al. JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. J Clin Invest 2009;119:1558–1570.
42. Chang Q, Chen J, Beezhold KJ et al. JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer 2009;8:64.

www.StemCellsTM.com

© 2017 The Authors

STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

ID: srinivasanvy Time: 19:12 I Path: //chenas03/Cenpro/ApplicationFiles/Journals/Wiley/SCTMVol010603/160006/Comp/APFFiles/JW-SCTM160006
Zhang J, Chong CC, Chen GG et al. A seven-microRNA expression signature predicts survival in hepatocellular carcinoma. PLoS One 2015;10:e0128628.

Ying Q, Liang L, Guo W et al. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology 2011;54:2064–2075.

Shi L, Wu L, Chen Z et al. MiR-141 activates Nrf2-dependent antioxidant pathway via down-regulating the expression of Keap1 conferring the resistance of hepatocellular carcinoma cells to 5-fluorouracil. Cell Physiol Biochem 2015;35:2333–2348.

Li L, Guo Z, Wang J et al. Serum mir-18a: A potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci 2012;57:2910–2916.

Okajima W, Komatsu S, Ichikawa D et al. Circulating microRNA profiles in plasma: Identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function. Oncotarget 2016;7:53820–53836.

Yamashita T, Budhu A, Forgues M et al. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007;67:10831–10839.

Voloshanenko O, Erdmann G, Dubash TD et al. Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. Nature Commun 2013;4:2610.

See www.StemCellsTM.com for supporting information available online.